T-cell lymphoma secondary to checkpoint inhibitor therapy.
Kartik AnandJoe EnsorSai Ravi PingaliPatrick HwuMadeleine DuvicStephen ChiangRoberto MirandaYouli ZuSwaminathan P IyerPublished in: Journal for immunotherapy of cancer (2020)
T-cell lymphoma is a rare sequela of ICIs with high mortality. Larger studies with long-term follow-up of patients receiving ICIs is needed.